TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26427789
Drug: Topical Matricaria
Normalized name: Matricaria chamomilla flowering top oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Matricaria recutita L (chamomile) oil
Study: 26123824
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen trometamol 25 mg plus tramadol hydrochloride 75 mg
Study: 26123824
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen trometamol 12.5 mg plus tramadol hydrochloride 37.5 mg
Study: 9882082
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen trometamol 25 mg
Study: 26123824
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride 75 mg
Study: 26123824
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride 37.5 mg
Study: 23853029
Drug: AFQ056 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFQ056 200 mg daily
Study: 23853029
Drug: AFQ056 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFQ056 50 mg daily
Study: 16585866
Drug: Hydrocodone/acetaminophen 7.5/750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/acetaminophen 7.5/750 mg
Study: 11556458
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac tromethamine
Study: 9628270
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin administered i.v. by continuous infusion for 7 days, followed by daily s.c. injections for 6 months. Intravenous insulin infusions were repeated every 12 months.
Study: 2736431
Drug: Azelastine 8.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 8.8 mg
Study: 2904931
Drug: Azelastine 17.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 17.6 mg
Study: 30597523
Drug: Weight reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight reduction and IVF treatment (n = 160)
Study: 26432647
Drug: remedē System
Approvals — FDA: no, EMA: no, PMDA: no
Description: remedē System therapy initiated at 1 month after implantation
Study: 26432647
Drug: remedē System
Approvals — FDA: no, EMA: no, PMDA: no
Description: remedē System therapy
Study: 21071527
Drug: Nasal cannula
Normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal cannula with continuous flow at 2 L/min
Study: 21071527
Drug: Nasal cannula
Normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal cannula with oxygen-conserving device at 2 L/min
Study: 21071527
Drug: Nasal cannula
Normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal cannula with portable oxygen concentrator at 2 L/min
Study: 19864035
Drug: Transarterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transarterial infusion chemotherapy (TAI) with zinostatin stimalamer
Study: 11824325
Drug: Combined radio-chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radio-chemotherapy (cisplatin 75 mg/m2 d1, etoposide 120 mg/m2 d1-3, Ifosfamid 1.5 mg/m2 d1-4, 3 cycles)
Study: 2368889
Drug: Thiopentone 4
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 4 mg.kg‐1
Study: 2466389
Drug: Diazepam 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.15 mg kg‐1 orally 2 hours before operation (Group III)
Study: 2466389
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet 2 hours before operation (Group IV)
Study: 26882102
Drug: Recombinant Human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant Human Interferon α1b therapy (rHuIFN‐α1b)
Study: 22889285
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser as an adjunct to mechanical debridement
Study: 15915010
Drug: Formoterol pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol pMDI (cumulative doses up to 96 microg)
Study: 15915010
Drug: Formoterol DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol DPI (cumulative doses up to 96 microg)
Study: 12409652
Drug: gemcitabine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine with or without a farnesyl transferase inhibitor
Study: 12409652
Drug: histone deacetylase
Normalized name: Histone deacetylase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: histone deacetylase inhibitor
Study: 12409652
Drug: 9‐nitrocamptothecin (topoisomerase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9‐nitrocamptothecin (topoisomerase I inhibitor)
Study: 12409652
Drug: oxaliplatin to
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatin to high‐dose 5FU plus leucovorin
Study: 7589056
Drug: Microemulsion formulation
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion formulation of cyclosporin at 200 mg
Study: 7589056
Drug: Microemulsion formulation
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion formulation of cyclosporin at 800 mg
Study: 2237853
Drug: 100-150 mg
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100-150 mg acetylsalicylic acid per day for prophylaxis after acute myocardial infarction
Study: 2237853
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg acetylsalicylic acid for cerebrovascular indications
Study: 109916
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg disodium cromoglycate (DSCG) inhaled with a spinhaler 30 minutes before exercise
Study: 109916
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of ketotifen taken orally 3 hours before exercise
Study: 109916
Drug: Placebo powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo powder inhaled with a spinhaler
Study: 31769533
Drug: Gluten (6-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten (6-g gluten protein)
Study: 28117400
Drug: Phytosterols-enriched low-fat
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterols-enriched low-fat milk (1.5 g phytosterols per day)
Study: 23702253
Drug: Grape seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape seed extract (GSE) 300 mg/d
Study: 9272408
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral ketotifen daily
Study: 9272408
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral ketotifen daily
Study: 7871077
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg sarmazenil
Study: 7871077
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg sarmazenil
Study: 3544792
Drug: verapamil-SR, 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil-SR, 240 mg twice daily
Study: 3544792
Drug: regular formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: regular formulation of verapamil, 120 mg 4 times daily
Study: 31595482
Drug: Inactivated quadrivalent
Normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated quadrivalent influenza vaccine (IIV4)
Study: 26462707
Drug: BMS 914392
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS 914392 (10 mg OD)
Study: 26462707
Drug: BMS 914392
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS 914392 (10 mg TDS)
Study: 26462707
Drug: BMS 914392
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS 914392 (20 mg TDS)
Study: 12243291
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine injection after combined spinal anaesthesia
Study: 12243291
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine injection after epidural anaesthesia
Study: 7560628
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg, n = 22)
Study: 7560628
Drug: Ibopamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (100 mg three times a day, n = 19)
Study: 2827044
Drug: Diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120 mg twice daily)
Study: 1963183
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Diltiazem + Atenolol)
Study: 30028922
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO2) therapy
Study: 21694614
Drug: Mifepristone (300,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (300, 600, or 1200 mg)
Study: 21694614
Drug: Mifepristone (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (plasma concentrations > 1660 ng/mL)
Study: 16418022
Drug: Bilateral superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superficial cervical plexus block with 0.75% ropivacaine administered before surgery (PRE group)
Study: 16418022
Drug: Bilateral superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superficial cervical plexus block with 0.75% ropivacaine administered after surgery (POST group)
Study: 10693082
Drug: Environmental exposures
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Environmental exposures to perchlorate (up to 15 micrograms/L)
Study: 9465587
Drug: EBRT combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT combined with BRTX (mean dose 50.2 +/- 13.2 Gy, dose rate of 0.3-0.4 Gy/hr)
Study: 9465587
Drug: Standard EBRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard EBRT (mean dose 51.5 +/- 12.4 Gy in 2.0 Gy fractions)
Study: 3332129
Drug: 10 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 Gy single dose TBI (n = 27)
Study: 3332129
Drug: 9.2 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.2 Gy single dose TBI (n = 22)
Study: 3332129
Drug: 9.2 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.2 Gy single dose TBI
Study: 3332129
Drug: 9.2 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.2 Gy single dose TBI and 10 Gy single dose TBI
Study: 26669919
Drug: Ixekizumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab treatment
Study: 24767551
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic paste (metronidazole, ciprofloxacin, and minocycline) (TAP)
Study: 24767551
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcium hydroxide and 2% chlorhexidine gel (CHP)
Study: 20056686
Drug: Kaletra tablets
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kaletra tablets (400 mg of lopinavir)
Study: 20056686
Drug: Lopimune granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopimune granules (400 mg of lopinavir)
Study: 20056686
Drug: Lopimune paediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopimune paediatric tablets (400 mg of lopinavir)
Study: 20056686
Drug: Kaletra solution
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kaletra solution with food
Study: 20056686
Drug: Lopimune formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopimune formulations
Study: 15630410
Drug: val66met SNP
Normalized name: SNP-ACTH (1-39)
Approvals — FDA: no, EMA: no, PMDA: no
Description: val66met SNP (allele G) in schizophrenia group
Study: 14738367
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of video and text information
Study: 10370680
Drug: Interferon-alpha administered
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha administered 6 million units subcutaneously daily for 2 weeks, then thrice weekly for 6 months (Group A)
Study: 10370680
Drug: Interferon-alpha administered
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha administered 6 million units thrice weekly for 6 months (Group B)
Study: 10370680
Drug: Interferon-alpha administered
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha administered 6 million units subcutaneously daily for 2 weeks, then thrice weekly for 6 months (Group A) in intermediate viral load group
Study: 10370680
Drug: Interferon-alpha administered
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha administered 6 million units thrice weekly for 6 months (Group B) in intermediate viral load group
Study: 10370680
Drug: Interferon-alpha administered
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha administered 6 million units subcutaneously daily for 2 weeks, then thrice weekly for 6 months (Group A) in genotype 2 patients
Study: 10370680
Drug: Interferon-alpha administered
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha administered 6 million units thrice weekly for 6 months (Group B) in genotype 2 patients
Study: 8900905
Drug: Cholic acid
Normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cholic acid (500 mg/day for 4 weeks)
Study: 8900905
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (500 mg/day for 4 weeks)
Study: 8900905
Drug: Deoxycholic acid
Normalized name: Deoxycholic Acid
DrugBank: Deoxycholic acid (DB03619)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deoxycholic acid (500 mg/day for 4 weeks)
Study: 8900905
Drug: Paromomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin (1 g/day for 2 weeks)
Study: 1807272
Drug: Inhaled toxic
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled toxic chemicals (phenol <0.0025 ppm, ethyl alcohol <0.5 ppm, formaldehyde <0.2 ppm, chlorine <0.3 ppm, pesticide 2,3-D <0.0034 ppm)
Study: 25186158
Drug: Automated closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated closed-loop insulin delivery
Study: 24963110
Drug: Sensor-augmented insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensor-augmented insulin pump therapy (SAP)
Study: 10613232
Drug: Ultrasound gel
Normalized name: Ultrasound gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound gel
Study: 25347723
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication review
Study: 9498972
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (Azmacort) oral inhaler 4 puffs twice daily (800 microg daily) for 7 days
Study: 9498972
Drug: IV hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV hydrocortisone (3 microg/kg/min) as a 14-h continuous infusion
Study: 22373835
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg/d
Study: 24773166
Drug: Sertraline 200
Normalized name: sertraline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 200 mg/d
Study: 26991958
Drug: Double-dorsal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dorsal injection
Study: 26991958
Drug: Single-volar injection
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-volar injection
Study: 22863660
Drug: CYD-TDV (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD-TDV (3 injections at months 0, 6, and 12)
Study: 22863660
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 injections at months 0 and 6) or pneumococcal polysaccharide vaccine (month 12)
Study: 22863660
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo or pneumococcal polysaccharide vaccine)
Study: 18775200
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg/d) with extended-release oxybutynin (10 mg/d)
Study: 18775200
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg/d) alone (Control)
Study: 11450709
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g/day)
Study: 2896581
Drug: HRP112 (depot‐medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRP112 (depot‐medroxyprogesterone acetate, 25mg and estradiol cypionate, 5 mg)
Study: 2692962
Drug: HRP102 (norethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRP102 (norethisterone enantate, 50 mg and estradiol valerate, 5 mg)
Study: 31954199
Drug: Oral Glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucose Tolerance Test (OGTT) - 300 kcal
Study: 30659702
Drug: Weekly prompted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly prompted BP self-monitoring and healthy behavior text messages
Study: 25559659
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 1,200 mg starting two days before the operation, in addition to isonitrogenous and isocaloric total parenteral nutrition.
Study: 23321948
Drug: Tagged vaginal
Normalized name: ALLERGENIC EXTRACT, TAG ALDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tagged vaginal gel (4 mL of tenofovir placebo gel with 15 mg 2‐pentyl acetate)
Study: 23321948
Drug: Tagged condom
Normalized name: ALLERGENIC EXTRACT, TAG ALDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tagged condom (with 15 mg 2‐butyl acetate)
Study: 19526810
Drug: Point injection
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point injection of red-sage-root (Danshen) in 5 ml normal saline, 2.5 ml per point, 3 times a week for 6 months
Study: 24520783
Drug: Routine Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Western medicine (Control)
Study: 9504446
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg/diltiazem ER 120 mg (E5/D120)
Study: 9504446
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg/diltiazem ER 180 mg (E5/D180)
Study: 9504446
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of enalapril/diltiazem ER (E/D)
Study: 8002149
Drug: Itraconazole, 100
Normalized name: Itraconazole, 100 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole, 100 mg daily for 6 weeks
Study: 8002149
Drug: Griseofulvin, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin, 500 mg daily for 6 weeks
Study: 3400564
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg three times a day in 10 patients and four times a day in 9 patients)
Study: 3400564
Drug: Digoxin (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.125 mg/day in 2 patients and 0.250 mg/day in 17 patients)
Study: 28100529
Drug: Tablet computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet computer based interactive distraction (TAB)
Study: 28100529
Drug: Midazolam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.3 mg kg-1) (MDZ)
Study: 21724623
Drug: Pegnivacogin 1
Normalized name: Pegnivacogin
DrugBank: Pegnivacogin (DB06293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegnivacogin 1 mg/kg
Study: 21724623
Drug: Control agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control agent (anivamersen)
Study: 19633475
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/d alone (arm A)
Study: 19633475
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/d in combination with bortezomib 1.6 mg/m2 (arm B)
Study: 19633475
Drug: Erlotinib +/-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib +/- bortezomib in patients with epidermal growth factor receptor mutations
Study: 16752169
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg or 80 mg daily
Study: 9223713
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (isotonic saline)
Study: 7963104
Drug: combination thrombolytic
Normalized name: THROMBOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination thrombolytic therapy
Study: 30269747
Drug: Upright position,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upright position, 60 mg prasugrel
Study: 30269747
Drug: Supine position,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supine position, 60 mg prasugrel
Study: 18608053
Drug: Intravaginal gel
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal gel (microbicide)
Study: 11942734
Drug: Red Orange
Normalized name: TITANIUM DIOXIDE 2.32 g in 25 g CUTANEOUS CREAM [RED ORANGE JELLY BB SPF20 PA PLUS PLUS NO.1]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Orange Complex (ROC) 50 mg/d, orally
Study: 10512958
Drug: Freehand tooth
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freehand tooth preparations